Tyra-300
Superficial Urinary Bladder Carcinoma
Explore 3 assets in Superficial Urinary Bladder Carcinoma →Floatz Rating
CCC48/100
Confidence
Indicative
Sponsor
Tyra Biosciences, Inc
Modality
UNKNOWN
Development Phase
Phase 1/2
Status
Active
Evidence ledger · v0.2
Clinical Evidence
Clinical track record: trial progression, reported outcomes, safety signals, and endpoint quality.
33Indicative
Detailed axis rationale is planned and will be published soon.
| Trial | Phase | Status | N | Primary endpoint | Readout |
|---|---|---|---|---|---|
NCT05544552CT.gov Safety and Preliminary Anti-Tumor Activity of TYRA-300 in Advanced Urothelial Carcinoma and Other Solid Tumors With FGFR3 Gene Alterations | — | Active Not Recruiting | — | — | — |
Competitive Position
Competitive setting: how crowded the indication is, class-level failures, and timing against rivals.
95Indicative
Detailed axis rationale is planned and will be published soon.
Same indication · Superficial Urinary Bladder Carcinoma
| Asset | Sponsor | Phase | Rating |
|---|---|---|---|
| Tyra-300 (this asset) | Tyra Biosciences, Inc | P1/2 | CCC · 48 |
| Pembrolizumab | Merck Sharp & Dohme LLC | P3 | B |
| Bacillus Calmette-Guerin Live Antigen, Unspecified Substrain | Merck Sharp & Dohme LLC | P3 | B |
| Pvsripo (Chimeric Poliovirus (Pv), Consisting Of The Type-1 Sabin Vaccine Strain Carrying A Foreign Internal Ribosome Entry Site (Ires) From Human Rhinovirus Type-2) (Hrv2) | Istari Oncology, Inc. | P1/2 | CC |
Other indications for Tyra-300
| Indication | Sponsor | Phase | Rating |
|---|---|---|---|
| Urothelial Carcinoma | — | P1/2 | CCC · 48 |
| Urinary System Neoplasm | — | P1/2 | CCC · 48 |
| Urinary Bladder Carcinoma | — | P1/2 | CC · 43 |
Scientific Foundation
Strength of the underlying biology: target validation, tractability, modality fit, and how related mechanisms have fared.
NR
Planned for methodology v0.2.
Development Feasibility
How realistically the program can be executed, drawing on modality precedent, enrollment dynamics, and sponsor delivery.
NR
Planned for methodology v0.2.
Commercial Opportunity
Commercial prize: addressable population, unmet need, and the value case for the indication.
NR
Planned for methodology v0.2.
IP & Exclusivity
Exclusivity position, covering patent protection and freedom-to-operate runway.
NR
Planned for methodology v0.2.
Manufacturing & Supply
Manufacturing and supply readiness, driven by modality process and scale-up risk.
NR
Planned for methodology v0.2.
Related assets
- PembrolizumabMerck Sharp & Dohme LLCB
- Bacillus Calmette-Guerin Live Antigen, Unspecified SubstrainMerck Sharp & Dohme LLCB
- Pvsripo (Chimeric Poliovirus (Pv), Consisting Of The Type-1 Sabin Vaccine Strain Carrying A Foreign Internal Ribosome Entry Site (Ires) From Human Rhinovirus Type-2) (Hrv2)Istari Oncology, Inc.CC
Citation
Floatz Terminal. Tyra-300 in Superficial Urinary Bladder Carcinoma. Methodology v0.2. Rated under v0.2 effective July 8, 2026. Last refreshed July 8, 2026. Accessed July 14, 2026. https://terminal.floatz.ai/assets/tyra-300-superficial-urinary-bladder-carcinoma
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →